Clinical Trial Update: SYNERGY: Open Study of Enoxaparin Versus Unfractionated Heparin in Patients With Acute Coronary Syndromes [Phase 3]

View source ↗

Summary

Phase 3 SYNERGY trial comparing enoxaparin to unfractionated heparin in patients with acute coronary syndromes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Myocardial Ischemia
• Unstable Angina

Drugs mentioned

• Enoxaparin (enoxaparin sodium)
• Unfractionated Heparin (unfractionated heparin)

Snippet

Sponsor: Sanofi | Conditions: Unstable Angina, Myocardial Infarction | Phase 3 | Status: COMPLETED